B-cell enrichment predictive of immunotherapy response in melanoma, sarcoma and kidney cancer
(University of Texas M. D. Anderson Cancer Center) Multiple studies out in Nature indicate that a patient's response to immune checkpoint blockade may depend on B cells located in special structures within the tumor. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 15, 2020 Category: Cancer & Oncology Source Type: news
Public Insurance Tied to Lower Cancer Survival in Young Patients
FRIDAY, Dec. 27, 2019 -- Young, low-income patients with bone or soft tissue sarcomas have decreased overall survival (OS), regardless of disease stage at presentation, according to a study published online Dec. 15 in Cancer Medicine.
Neela L.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 27, 2019 Category: Pharmaceuticals Source Type: news
Teenager with incurable cancer refuses to stop smiling despite spending Christmas in hospital
Joseph Lunn, from Mitcham, south London, was diagnosed with synovial sarcoma, a rare and incurable cancer in his abdomen. He had four tumours removed over Christmas. (Source: the Mail online | Health)
Source: the Mail online | Health - December 27, 2019 Category: Consumer Health News Source Type: news
Combination of chemo and diabetes drugs shows potential for treating Ewing sarcoma
(Houston Methodist) Houston Methodist researchers propose a combination of two well-known drugs as a new treatment option for Ewing sarcoma -- one of them typically used to treat diabetes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 16, 2019 Category: Cancer & Oncology Source Type: news
SP-2577 Granted Fast Track Designation by the FDA for Patients with Ewing Sarcoma
The drug is currently the subject of an ongoing phase I/II clinical study for the treatment of patients with Ewing sarcoma who have relapsed or are refractory to standard-of-care therapy. (Source: CancerNetwork)
Source: CancerNetwork - December 16, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Medtech in a Minute: 3M Quits Drug-Delivery, New FDA Commissioner, and More
It's Official, Hahn Will Lead FDA
The U.S. Senate voted 72-18 to confirm Stephen Hahn, MD, as the new FDA Commissioner. The news has been well received by industry advocacy groups like AdvaMed and professional societies like the American Heart Association. Hahn is a radiation oncologist who specializes in treating lung cancer and sarcoma.
Â
3M Calls It Quits on Drug Delivery
The company plans to sell most of its drug-delivery business to an affiliate of Altaris Capital Partners for $650 million plus a 17% noncontrolling interest...
Source: MDDI - December 13, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news
It & #039;s Official, Hahn Will Lead FDA
FDA officially has a new boss. The U.S. Senate voted 72-18 on Thursday to confirm Stephen Hahn, MD, as the new FDA Commissioner. The news was largely well received by industry advocacy groups like AdvaMed and professional societies like the American Heart Association.
“Dr. Hahn is an excellent choice to lead FDA, and we congratulate him on his swift and overwhelming bipartisan confirmation," said AdvaMed CEO Scott Whitaker. "During the confirmation process, Dr. Hahn demonstrated his deep understanding of the agency’s mission to protect and ...
Source: MDDI - December 13, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Regulatory and Compliance Source Type: news
Adaptimmune gets FDA designation to accelerate development of cancer therapy
The Food and Drug Administration has awarded a key designation to a therapy Adaptimmune is developing for a rare type of cancer.
Adaptimmune's experimental T-cell therapy, called ADP-A2M4, targets synovial sarcoma, a cancer that occurs primarily in the extremities of the arms or legs. About two people out of every one million are diagnosed with the condition annually.
The FDA designated ADP-42M4 as a regenerative medicine advanced therapy. That designation, established as part of the 21st Century… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 3, 2019 Category: Pharmaceuticals Authors: John George Source Type: news
Markedly Elevated Sarcoma Risk in Long-Term Survivors of Hereditary Retinoblastoma Markedly Elevated Sarcoma Risk in Long-Term Survivors of Hereditary Retinoblastoma
The risk of bone and soft-tissue sarcoma is markedly elevated in long-term survivors of hereditary retinoblastoma treated with radiation, researchers report.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - November 26, 2019 Category: Orthopaedics Tags: Hematology-Oncology News Source Type: news
Turning key metabolic process back on could make sarcoma more susceptible to treatment
(University of Pennsylvania School of Medicine) Soft tissue sarcoma cells stop a key metabolic process which allows them to multiply and spread, and so restarting that process could leave these cancers vulnerable to a variety of treatments (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - November 26, 2019 Category: Biology Source Type: news
Neoadjuvant Chemotherapy for Primary Sarcoma of the Breast Neoadjuvant Chemotherapy for Primary Sarcoma of the Breast
This case suggests that breast sarcomas could be treated in the same way as other soft tissue sarcomas in terms of adjuvant chemotherapy.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 20, 2019 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
Day-glo dye helps surgeons to trace the trickiest tumours
British doctors are using the substance to help identify a type of cancer called sarcomas, which affect thousands every year. The new technique could spare some patients limb amputations. (Source: the Mail online | Health)
Source: the Mail online | Health - November 16, 2019 Category: Consumer Health News Source Type: news
Gene Editing Tool Fights Cancer in Early Study
So far, CRISPR has only been tried in three patients, two with multiple myeloma and one with a sarcoma. All had tried standard treatments, to no avail. (Source: WebMD Health)
Source: WebMD Health - November 7, 2019 Category: Consumer Health News Source Type: news
CRISPR-Edited T Cells Used in Cancer Patients for the First Time in the US
The initial findings from a small clinical trial of patients with multiple myeloma or sarcoma suggest that gene-edited immunotherapy is safe. (Source: The Scientist)
Source: The Scientist - November 6, 2019 Category: Science Tags: News & Opinion Source Type: news
Trump Nominates Stephen Hahn to Be the New FDA Commissioner
Stephen Hahn, a chief medical executive at the MD Anderson Cancer Center, has been tapped by President Trump to be the new FDA commissioner. The 59-year-old is a radiation oncologist that specializes in treating lung cancer and sarcoma. He has authored 220 peer-reviewed original research articles.
AdvaMed was highly supportive of the decision giving Hahn praise. In a release, the device-advocacy agency said, “We congratulate Dr. Hahn on his nomination to lead FDA, and we hope the Senate moves swiftly to confirm him. Dr. Hahn’s distinguished career as a healthcare provider and researcher...
Source: MDDI - November 4, 2019 Category: Medical Devices Authors: Omar Ford Tags: Regulatory and Compliance Source Type: news
